Journal
JOURNAL OF GASTROENTEROLOGY
Volume 45, Issue 2, Pages 195-203Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s00535-009-0132-9
Keywords
Autophagy; Autophagosome; HCV replicon; Chloroquine
Categories
Funding
- Grants-in-Aid for Scientific Research [21570155] Funding Source: KAKEN
Ask authors/readers for more resources
Autophagy has been reported to play a pivotal role on the replication of various RNA viruses. In this study, we investigated the role of autophagy on hepatitis C virus (HCV) RNA replication and demonstrated anti-HCV effects of an autophagic proteolysis inhibitor, chloroquine. Induction of autophagy was evaluated following the transfection of HCV replicon to Huh-7 cells. Next, we investigated the replication of HCV subgenomic replicon in response to treatment with lysosomal protease inhibitors or pharmacological autophagy inhibitor. The effect on HCV replication was analyzed after transfection with siRNA of ATG5, ATG7 and light-chain (LC)-3 to replicon cells. The antiviral effect of chloroquine and/or interferon-alpha (IFN alpha) was evaluated. The transfection of HCV replicon increased the number of autophagosomes to about twofold over untransfected cells. Pharmacological inhibition of autophagic proteolysis significantly suppressed expression level of HCV replicon. Silencing of autophagy-related genes by siRNA transfection significantly blunted the replication of HCV replicon. Treatment of replicon cells with chloroquine suppressed the replication of the HCV replicon in a dose-dependent manner. Furthermore, combination treatment of chloroquine to IFN alpha enhanced the antiviral effect of IFN alpha and prevented re-propagation of HCV replicon. Protein kinase R was activated in cells treated with IFN alpha but not with chloroquine. Incubation with chloroquine decreased degradation of long-lived protein leucine. The results of this study suggest that the replication of HCV replicon utilizes machinery involving cellular autophagic proteolysis. The therapy targeted to autophagic proteolysis by using chloroquine may provide a new therapeutic option against chronic hepatitis C.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available